[1]
|
Rawla, P. (2019) Epidemiology of Prostate Cancer. World Journal of Oncology, 10, 63-89.
https://doi.org/10.14740/wjon1191
|
[2]
|
Stangelberger, A., Waldert, M. and Djavan, B. (2008) Prostate Cancer in Elderly Men. Reviews in Urology, 10, 111-119.
|
[3]
|
叶定伟. 前列腺癌的流行病学和中国的发病趋势[J]. 中华外科杂志, 2006, 44(6): 362-364.
|
[4]
|
Pagliarulo, V., Bracarda, S., Eisenberger, M.A., et al. (2012) Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. European Urology, 61, 11-25. https://doi.org/10.1016/j.eururo.2011.08.026
|
[5]
|
Tannock, I.F., De Wit, R., Berry, W.R., et al. (2004) Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. The New England Journal of Medicine, 351, 1502-1512.
https://doi.org/10.1056/NEJMoa040720
|
[6]
|
Dayyani, F., Gallick, G.E., Logothetis, C.J., et al. (2011) Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. Journal of the National Cancer Institute, 103, 1665-1675. https://doi.org/10.1093/jnci/djr362
|
[7]
|
Robinson, D., Van Allen, E.M., Wu, Y.M., et al. (2015) Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 161, 1215-1228. https://doi.org/10.1016/j.cell.2015.05.001
|
[8]
|
Buttigliero, C., Tucci, M., Bertaglia, V., et al. (2015) Understanding and Overcoming the Mechanisms of Primary and Acquired Resistance to Abiraterone and Enzalutamide in Castration Resistant Prostate Cancer. Cancer Treatment Reviews, 41, 884-892. https://doi.org/10.1016/j.ctrv.2015.08.002
|
[9]
|
De Bono, J.S., Logothetis, C.J., Molina, A., et al. (2011) Abiraterone and Increased Survival in Metastatic Prostate Cancer. The New England Journal of Medicine, 364, 1995-2005. https://doi.org/10.1056/NEJMoa1014618
|
[10]
|
Ryan, C.J., Smith, M.R., De Bono, J.S., et al. (2013) Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. The New England Journal of Medicine, 368, 138-148. https://doi.org/10.1056/NEJMoa1209096
|
[11]
|
Sternberg, C.N., Molina, A., North, S., et al. (2013) Effect of Abiraterone Acetate on Fatigue in Patients with Metastatic Castration-Resistant Prostate Cancer after Docetaxel Chemotherapy. Annals of Oncology, 24, 1017-1025.
https://doi.org/10.1093/annonc/mds585
|
[12]
|
Harland, S., Staffurth, J., Molina, A., et al. (2013) Effect of Abiraterone Acetate Treatment on the Quality of Life of Patients with Metastatic Castration-Resistant Prostate Cancer after Failure of Docetaxel Chemotherapy. European Journal of Cancer, 49, 3648-3657. https://doi.org/10.1016/j.ejca.2013.07.144
|
[13]
|
Logothetis, C.J., Basch, E., Molina, A., et al. (2012) Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial. The Lancet Oncology, 13, 1210-1217. https://doi.org/10.1016/S1470-2045(12)70473-4
|
[14]
|
Pereira-Salgado, A., Kwan, E.M., Tran, B., et al. (2021) Systematic Review of Efficacy and Health Economic Implications of Real-World Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? European Urology Focus, 7, 752-763. https://doi.org/10.1016/j.euf.2020.03.003
|
[15]
|
Tran, C., Ouk, S., Clegg, N.J., et al. (2009) Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science, 324, 787-790. https://doi.org/10.1126/science.1168175
|
[16]
|
Scher, H.I., Fizazi, K., Saad, F., et al. (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. The New England Journal of Medicine, 367, 1187-1197. https://doi.org/10.1056/NEJMoa1207506
|
[17]
|
Khalaf, D.J., Annala, M., Taavitsainen, S., et al. (2019) Optimal Sequencing of Enzalutamide and Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: A Multicentre, Randomised, Open-Label, Phase 2, Crossover Trial. The Lancet Oncology, 20, 1730-1739. https://doi.org/10.1016/S1470-2045(19)30688-6
|
[18]
|
Maughan, B.L., Luber, B., Nadal, R., et al. (2017) Comparing Sequencing of Abiraterone and Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. Prostate, 77, 33-40.
https://doi.org/10.1002/pros.23246
|
[19]
|
Antonarakis, E.S., Lu, C., Luber, B., et al. (2015) Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 1, 582-591.
https://doi.org/10.1001/jamaoncol.2015.1341
|
[20]
|
Sciarra, A., Gentilucci, A., Silvestri, I., et al. (2019) Androgen Receptor Variant 7 (AR-V7) in Sequencing Therapeutic Agents for Castratrion Resistant Prostate Cancer: A Critical Review. Medicine (Baltimore), 98, e15608.
https://doi.org/10.1097/MD.0000000000015608
|
[21]
|
Esch, L., Schulz, W.A. and Albers, P. (2014) Sequential Treatment with Taxanes and Novel Anti-Androgenic Compounds in Castration-Resistant Prostate Cancer. Oncology Research and Treatment, 37, 492-498.
https://doi.org/10.1159/000365530
|
[22]
|
Lorente, D., Mateo, J., Perez-Lopez, R., et al. (2015) Sequencing of Agents in Castration-Resistant Prostate Cancer. The Lancet Oncology, 16, e279-e292. https://doi.org/10.1016/S1470-2045(15)70033-1
|
[23]
|
Ang, J.E., Olmos, D. and De Bono, J.S. (2009) CYP17 Blockade by Abiraterone: Further Evidence for Frequent Continued Hormone-Dependence in Castration-Resistant Prostate Cancer. British Journal of Cancer, 100, 671-675.
https://doi.org/10.1038/sj.bjc.6604904
|
[24]
|
Devore, N.M. and Scott, E.E. (2012) Structures of Cytochrome P450 17A1 with Prostate Cancer Drugs Abiraterone and TOK-001. Nature, 482, 116-119. https://doi.org/10.1038/nature10743
|
[25]
|
Bouhajib, M. and Tayab, Z. (2019) Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. Clinical Drug Investigation, 39, 309-317. https://doi.org/10.1007/s40261-019-00752-1
|
[26]
|
Chi, K.N., Spratlin, J., Kollmannsberger, C., et al. (2015) Food Effects on Abiraterone Pharmacokinetics in Healthy Subjects and Patients with Metastatic Castration-Resistant Prostate Cancer. The Journal of Clinical Pharmacology, 55, 1406-1414. https://doi.org/10.1002/jcph.564
|
[27]
|
Szmulewitz, R.Z., Peer, C.J., Ibraheem, A., et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone with Food versus Standard Dose Abiraterone in Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 36, 1389-1395. https://doi.org/10.1200/JCO.2017.76.4381
|
[28]
|
Del Re, M., Fogli, S., Derosa, L., et al. (2017) The Role of Drug-Drug Interactions in Prostate Cancer Treatment: Focus on Abiraterone Acetate/Prednisone and Enzalutamide. Cancer Treatment Reviews, 55, 71-82.
https://doi.org/10.1016/j.ctrv.2017.03.001
|
[29]
|
Monbaliu, J., Gonzalez, M., Bernard, A., et al. (2016) In Vitro and in Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. Drug Metabolism & Disposition, 44, 1682-1691. https://doi.org/10.1124/dmd.116.070672
|
[30]
|
Auchus, R.J., Yu, M.K., Nguyen, S., et al. (2014) Use of Prednisone with Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer. Oncologist, 19, 1231-1240. https://doi.org/10.1634/theoncologist.2014-0167
|
[31]
|
Fenioux, C., Louvet, C., Charton, E., et al. (2019) Switch from Abiraterone plus Prednisone to Abiraterone plus Dexamethasone at Asymptomatic PSA Progression in Patients with Metastatic Castration-Resistant Prostate Cancer. BJU International, 123, 300-306. https://doi.org/10.1111/bju.14511
|
[32]
|
杨振宇, 叶阳天, 李志勇, 等. 泼尼松转换为地塞米松治疗mCRPC的疗效分析[J]. 中华泌尿外科杂志, 2020, 41(8): 597-602.
|
[33]
|
Colomba, E., Marret, G., Baciarello, G., et al. (2020) Liver Tests Increase on Abiraterone Acetate in Men with Metastatic Prostate Cancer: Natural History, Management and Outcome. European Journal of Cancer, 129, 117-122.
https://doi.org/10.1016/j.ejca.2020.01.017
|